The rapid growth of biopharma is causing a shift to a new paradigm for the drug development and delivery model. In the same manner that the personal computing industry grew and developed business models that fit the way products were sourced, constructed and delivered, a business model for biopharma is taking shape.
Image: https://www.biospace.com
{iframe}https://www.biospace.com/article/agt-ceo-jeff-galvin-on-the-future-of-the-gene-and-cell-therapy-industry/?TrackID=16{/iframe}